Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company with a focus on rare neuroendocrine diseases. With a strong pipeline of potential treatments, including their main asset IMCIVREE, setmelanotide, and RM-718, the company is well-positioned for future growth in the United States and international markets. Upcoming catalysts, such as 6-month follow-up data from Phase II PWS study in 2Q26 and the initiation of a pivotal HO study with oral pill bivamelagon by YE'26, could further drive upside potential for the company. While recent updates have disappointed the market, the fundamental value proposition in Rhythm remains intact and the company is well-positioned for future growth.

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company that focuses on developing therapies for rare neuroendocrine diseases. While the company has a promising drug in development, it faces challenges such as potential hyperpigmentation side effects and dependency on regulatory approval. Additionally, the company's market opportunity for its main drug, Imcivree, is currently underappreciated, and there is potential for competition in the future. Therefore, the outlook for Rhythm Pharmaceuticals is negative, and its stock may not perform well in the long term.